RAPACT 5MG TABLETS | EVEROLIMUS | MHP - PowerPoint PPT Presentation

About This Presentation
Title:

RAPACT 5MG TABLETS | EVEROLIMUS | MHP

Description:

Rapact 5mg is a derivative of Rapamycin (sirolimus) and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. – PowerPoint PPT presentation

Number of Views:22

less

Transcript and Presenter's Notes

Title: RAPACT 5MG TABLETS | EVEROLIMUS | MHP


1
RAPACT 5MG TABLETS EVEROLIMUS MHP
  • Million Health Pharmaceuticals

2
DESCRIPTION
  • Rapact 5mg is a derivative of Rapamycin
    (sirolimus) and works similarly to Rapamycin as
    an mTOR (mammalian target of rapamycin)
    inhibitor. It is normally used as an
    immunosuppressant to prevent rejection of organ
    transplants. In a similar fashion to other mTOR
    inhibitors Everolimus' effect is solely on the
    mTORC1 protein and not on the mTORC2 protein.

3
Renal carcinoma
4
PRESCRIBING INFORMATION
  • Rapact 5mg tablet are mainly indicated for the
    treatment of Renal carcinoma.Rapact 5mg
    tablet are mainly indicated for the treatment of
    Breast carcinoma.Rapact 5mg tablet are mainly
    indicated for the treatment of Brain
    carcinoma.Rapact 5mg is also used in various
    advanced stage cancer in stomach, intestines or
    pancreas.

5
MECHANISM OF ACTION
  • Everolimus is an mTOR prohibitor, joints at high
    compatibility to FK506 binding protein 12, via
    producing drug complex which inhibits the
    specific of mTOR.This inhibition decreases the
    activity of effectors downstream, that may cause
    blockage of cell progression from G1 into S
    phase, subsequently causes cell growth arrest and
    apoptosis

6
RAPACT 5MG
7
PRODUCT DETAILS
  • Brand Rapact Ingredients Everolimus Strength
    5mgManufactured Natco Pharma Ltd Package
    10 tablets 

8
PHARMACOKINETICS
  • ABSORPTION
  • The high plasma concentration time of Everolimus
    is 1 to 2 hours.The effect of food with Rapact
    5mg that with heavy meal Reduction of systemic
    exposure to Rapact 5mg10mg, and the high blood
    plasma concentration by 54.DISTRIBUTION
  • Rapact 5mg human plasma protein bound with the
    range of 74.METABOLISM
  • The metabolism of Everolimus is occurred in
    liver, which is a substrate of CYP3A4.

9
EXCRETION
  • The major route of elimination 5 in urine the
    parent compound has been detected in urine or
    feces. The half-life period of Everolimus is
    relatively 30 hours

10
DOSAGE MANAGEMENT
  • In breast cancer, renal cell cancer, pancreatic
    cancer, Neuro endocrine cancerThe prescribed
    dosage is 10mg should be taken as a single
    dose.In Brain or intracranial cancerThe
    prescribed dosage of Rapact 5mg is 4.5mg/m2
    orally as a single dose.In pediatricThe usual
    pediatric dosage of Rapact in brain or
    intracranial tumor is 4.5mg/m2 should be taken
    orally as a single dose. 

11
PRECAUTIONS
  • Lymphomas
  • Increased exposure of skin cancers, patient may
    protect from UV lightSerious infections
  • Patients receiving Rapact 5mg have high risk of
    acquiring various infections related to bacteria,
    virus, and fungi. Anti-microbial agents are
    preferred for the suspected patients.Hepatic
    artery thrombosis
  • In liver transplant patients, Rapact 5mg therapy
    should not be recommended.Nephrotoxicity
  • Renal function should be monitored frequently
    caution should be taken while using Rapact 5mg in
    renal impaired patients.

12
SIDE EFFECTS
  • Hypersensitivity reactions Lymphomas other
    malignancy Serious infections Kidney graft
    thrombosis Hepatic artery thrombosis
    Nephrotoxicity Hyperlipemia Angioedema
    Interstitial lung disease Thrombocytopenia
    Male infertility Proteinuria New commencement
    of diabetes .

13
DRUG INTERACTION
  •  Rapact 5mg interaction with strong inhibitor of
    CYP3A4, or P-gp, leads to cause decreasing the
    efflux of Everolimus and increase the plasma
    concentration of Everolimus. Combination
    of Rapact 5mg with verapamil leads to increasing
    the plasma concentration of Everolimus.
    Combination of Rapact 5mg with Atorvastatin or
    pravastatin causes rhabdomyolysis, due to
    increasing concentration of lipid lowering
    agents. Rapact 5mg combination with strong
    CYP3A4 inducers, causes increasing the exposure
    of Everolimus.

14
CONTRAINDICATIONS
  • Some anaphylactic reaction occurs, if patients
    are contraindicated to the components present in
    the Rapact 5mg tablet.

15
PREGNANCY
  • Pregnancy category C Rapact 5mg is needed only by
    the patients after knowing the benefits to the
    mother outweighs the risk to fetus.

16
STORAGE
  • Rapact 5mg tablet should be kept at 25CKeep the
    tablet away from moisture, heat and
    lightDispense only in original container.

17
MISSED DOSE
  • If patient failed to take a single dose, patients
    must consult with medical practitioner and follow
    the instructions given by them. Or the missed
    dose should be avoiding and follow the regular
    dosing schedule.

18
OVERDOSAGE
  • The over dosage of Everolimus is rarely occur, in
    case of over dosage patient must be provide with
    supportive measures. The acute toxicity of
    Everolimus over dosage should be monitored.

19
CONTACT DETAILS
  • PHONE NO91-9940472902
  • E-MAILmillionhealthpharmaceuticals_at_gmail.com
  • WEBSITE URLhttps//millionpharma.com/rapact-5-mg.
    php
Write a Comment
User Comments (0)
About PowerShow.com